https://www.selleckchem.com/pr....oducts/tinengotinib.
Economic evaluations of lifestyle interventions, which aim to prevent diabetes/cardiovascular disease (CVD), have not included dementia. Lifestyle interventions decrease dementia risk and extend life expectancy, leading to competing effects on health care costs. We aim to demonstrate the feasibility of including dementia in a public health cost-effectiveness analysis and quantify the overall impacts accounting for these competing effects. The School for Public Health Research (SPHR) diabetes prevention model describes individuals'
Like
Comment
Share
